Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies
Purpose of the Review We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidenc...
Gespeichert in:
| Veröffentlicht in: | Current psychiatry reports 2020-08, Vol.22 (8), p.37-37, Article 37 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 37 |
|---|---|
| container_issue | 8 |
| container_start_page | 37 |
| container_title | Current psychiatry reports |
| container_volume | 22 |
| creator | Stoffers-Winterling, Jutta Storebø, Ole Jakob Lieb, Klaus |
| description | Purpose of the Review
We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidence.
Recent Findings
We identified seven new RCTs, plus newly available data for an older RCT. Only three of these RCTs have been published in full text, while we found study data posted at trial registry platforms for the others.
Summary
The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. A large effectiveness study did not detect beneficial effects of lamotrigine in routine care. The prevalent use of medications in BPD is still not reflected or supported by the current evidence. More research is needed regarding the most commonly used substances and substance classes, i.e. SSRIs, and quetiapine, but also with respect to people presenting with distinct comorbid conditions. |
| doi_str_mv | 10.1007/s11920-020-01164-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7275094</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2409544546</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-c1ae8fc178584a133ca0960a07a91ac814effbf100372d216d1cffb1d7a6a4353</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEoqXwBzggS1w4EPD4I044INECbaVKXQn2bE1tZ9dV1t7aCdL--zpsP4ADh5E9nsevx_NW1WugH4BS9TEDdIzWdA6ARtTwpDoEyWVdEvl03jNe8xbYQfUi52taSNqy59UBZ5IKYOqwGhZrTBs0cVy7hNsd6WMixzFZlwYfHFm4lGPAwY878tXn34VPBANZbi2OjsSeLKarwee1s-_JMmzvk8JYchlW0YcV-TFO1rv8snrW45Ddq7v1qFp-__bz5Ky-uDw9P_lyURuhxFgbQNf2BlQrW4HAuUHaNRSpwg7QtCBc31_1ZQZcMcugsWDKAViFDQou-VH1ea9butk4a1wYEw56m_wG005H9PrvSvBrvYq_tGJK0k4UgXd3AineTC6PeuOzccOAwcUpayaA8kYJDgV9-w96HadUJjZTtJNCSNEUiu0pk2LOyfUPzQDVs5l6b6amc8xm6ln6zZ_feLhy714B-B7IpRRWLj2-_R_ZW4W5q8A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2409544546</pqid></control><display><type>article</type><title>Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Stoffers-Winterling, Jutta ; Storebø, Ole Jakob ; Lieb, Klaus</creator><creatorcontrib>Stoffers-Winterling, Jutta ; Storebø, Ole Jakob ; Lieb, Klaus</creatorcontrib><description>Purpose of the Review
We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidence.
Recent Findings
We identified seven new RCTs, plus newly available data for an older RCT. Only three of these RCTs have been published in full text, while we found study data posted at trial registry platforms for the others.
Summary
The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. A large effectiveness study did not detect beneficial effects of lamotrigine in routine care. The prevalent use of medications in BPD is still not reflected or supported by the current evidence. More research is needed regarding the most commonly used substances and substance classes, i.e. SSRIs, and quetiapine, but also with respect to people presenting with distinct comorbid conditions.</description><identifier>ISSN: 1523-3812</identifier><identifier>EISSN: 1535-1645</identifier><identifier>DOI: 10.1007/s11920-020-01164-1</identifier><identifier>PMID: 32504127</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Borderline personality disorder ; Borderline Personality Disorder - drug therapy ; Drug therapy ; Humans ; Lamotrigine ; Medicine ; Medicine & Public Health ; Personality disorders ; Personality Disorders (K Bertsch ; Personality Disorders (K Bertsch, Section Editor) ; Psychiatry ; Randomized Controlled Trials as Topic ; Section Editor ; Selective Serotonin Reuptake Inhibitors ; Self-Injurious Behavior ; Suicide ; Topical Collection on Personality Disorders</subject><ispartof>Current psychiatry reports, 2020-08, Vol.22 (8), p.37-37, Article 37</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-c1ae8fc178584a133ca0960a07a91ac814effbf100372d216d1cffb1d7a6a4353</citedby><cites>FETCH-LOGICAL-c474t-c1ae8fc178584a133ca0960a07a91ac814effbf100372d216d1cffb1d7a6a4353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11920-020-01164-1$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11920-020-01164-1$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32504127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stoffers-Winterling, Jutta</creatorcontrib><creatorcontrib>Storebø, Ole Jakob</creatorcontrib><creatorcontrib>Lieb, Klaus</creatorcontrib><title>Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies</title><title>Current psychiatry reports</title><addtitle>Curr Psychiatry Rep</addtitle><addtitle>Curr Psychiatry Rep</addtitle><description>Purpose of the Review
We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidence.
Recent Findings
We identified seven new RCTs, plus newly available data for an older RCT. Only three of these RCTs have been published in full text, while we found study data posted at trial registry platforms for the others.
Summary
The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. A large effectiveness study did not detect beneficial effects of lamotrigine in routine care. The prevalent use of medications in BPD is still not reflected or supported by the current evidence. More research is needed regarding the most commonly used substances and substance classes, i.e. SSRIs, and quetiapine, but also with respect to people presenting with distinct comorbid conditions.</description><subject>Borderline personality disorder</subject><subject>Borderline Personality Disorder - drug therapy</subject><subject>Drug therapy</subject><subject>Humans</subject><subject>Lamotrigine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Personality disorders</subject><subject>Personality Disorders (K Bertsch</subject><subject>Personality Disorders (K Bertsch, Section Editor)</subject><subject>Psychiatry</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Section Editor</subject><subject>Selective Serotonin Reuptake Inhibitors</subject><subject>Self-Injurious Behavior</subject><subject>Suicide</subject><subject>Topical Collection on Personality Disorders</subject><issn>1523-3812</issn><issn>1535-1645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU1v1DAQhiMEoqXwBzggS1w4EPD4I044INECbaVKXQn2bE1tZ9dV1t7aCdL--zpsP4ADh5E9nsevx_NW1WugH4BS9TEDdIzWdA6ARtTwpDoEyWVdEvl03jNe8xbYQfUi52taSNqy59UBZ5IKYOqwGhZrTBs0cVy7hNsd6WMixzFZlwYfHFm4lGPAwY878tXn34VPBANZbi2OjsSeLKarwee1s-_JMmzvk8JYchlW0YcV-TFO1rv8snrW45Ddq7v1qFp-__bz5Ky-uDw9P_lyURuhxFgbQNf2BlQrW4HAuUHaNRSpwg7QtCBc31_1ZQZcMcugsWDKAViFDQou-VH1ea9butk4a1wYEw56m_wG005H9PrvSvBrvYq_tGJK0k4UgXd3AineTC6PeuOzccOAwcUpayaA8kYJDgV9-w96HadUJjZTtJNCSNEUiu0pk2LOyfUPzQDVs5l6b6amc8xm6ln6zZ_feLhy714B-B7IpRRWLj2-_R_ZW4W5q8A</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Stoffers-Winterling, Jutta</creator><creator>Storebø, Ole Jakob</creator><creator>Lieb, Klaus</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200801</creationdate><title>Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies</title><author>Stoffers-Winterling, Jutta ; Storebø, Ole Jakob ; Lieb, Klaus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-c1ae8fc178584a133ca0960a07a91ac814effbf100372d216d1cffb1d7a6a4353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Borderline personality disorder</topic><topic>Borderline Personality Disorder - drug therapy</topic><topic>Drug therapy</topic><topic>Humans</topic><topic>Lamotrigine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Personality disorders</topic><topic>Personality Disorders (K Bertsch</topic><topic>Personality Disorders (K Bertsch, Section Editor)</topic><topic>Psychiatry</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Section Editor</topic><topic>Selective Serotonin Reuptake Inhibitors</topic><topic>Self-Injurious Behavior</topic><topic>Suicide</topic><topic>Topical Collection on Personality Disorders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stoffers-Winterling, Jutta</creatorcontrib><creatorcontrib>Storebø, Ole Jakob</creatorcontrib><creatorcontrib>Lieb, Klaus</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current psychiatry reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stoffers-Winterling, Jutta</au><au>Storebø, Ole Jakob</au><au>Lieb, Klaus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies</atitle><jtitle>Current psychiatry reports</jtitle><stitle>Curr Psychiatry Rep</stitle><addtitle>Curr Psychiatry Rep</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>22</volume><issue>8</issue><spage>37</spage><epage>37</epage><pages>37-37</pages><artnum>37</artnum><issn>1523-3812</issn><eissn>1535-1645</eissn><abstract>Purpose of the Review
We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidence.
Recent Findings
We identified seven new RCTs, plus newly available data for an older RCT. Only three of these RCTs have been published in full text, while we found study data posted at trial registry platforms for the others.
Summary
The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. A large effectiveness study did not detect beneficial effects of lamotrigine in routine care. The prevalent use of medications in BPD is still not reflected or supported by the current evidence. More research is needed regarding the most commonly used substances and substance classes, i.e. SSRIs, and quetiapine, but also with respect to people presenting with distinct comorbid conditions.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32504127</pmid><doi>10.1007/s11920-020-01164-1</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3812 |
| ispartof | Current psychiatry reports, 2020-08, Vol.22 (8), p.37-37, Article 37 |
| issn | 1523-3812 1535-1645 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7275094 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Borderline personality disorder Borderline Personality Disorder - drug therapy Drug therapy Humans Lamotrigine Medicine Medicine & Public Health Personality disorders Personality Disorders (K Bertsch Personality Disorders (K Bertsch, Section Editor) Psychiatry Randomized Controlled Trials as Topic Section Editor Selective Serotonin Reuptake Inhibitors Self-Injurious Behavior Suicide Topical Collection on Personality Disorders |
| title | Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A58%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacotherapy%20for%20Borderline%20Personality%20Disorder:%20an%20Update%20of%20Published,%20Unpublished%20and%20Ongoing%20Studies&rft.jtitle=Current%20psychiatry%20reports&rft.au=Stoffers-Winterling,%20Jutta&rft.date=2020-08-01&rft.volume=22&rft.issue=8&rft.spage=37&rft.epage=37&rft.pages=37-37&rft.artnum=37&rft.issn=1523-3812&rft.eissn=1535-1645&rft_id=info:doi/10.1007/s11920-020-01164-1&rft_dat=%3Cproquest_pubme%3E2409544546%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2409544546&rft_id=info:pmid/32504127&rfr_iscdi=true |